Medexus Pharmaceuticals (MDP) Competitors C$3.05 -0.02 (-0.65%) As of 09/4/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock MDP vs. EPI, ICC, RIV, LEAF, RX, CRDL, HLS, TGOD, NINE, and SUGRShould you be buying Medexus Pharmaceuticals stock or one of its competitors? The main competitors of Medexus Pharmaceuticals include ESSA Pharma (EPI), ICC Labs (ICC), RIV Capital (RIV), Leaf Mobile (LEAF), BioSyent (RX), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), and SugarBud Craft Growers (SUGR). These companies are all part of the "drug manufacturers - specialty & generic" industry. Medexus Pharmaceuticals vs. Its Competitors ESSA Pharma ICC Labs RIV Capital Leaf Mobile BioSyent Cardiol Therapeutics HLS Therapeutics Green Organic Dutchman Delta 9 Cannabis SugarBud Craft Growers ESSA Pharma (CVE:EPI) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation. Do insiders & institutionals believe in EPI or MDP? 0.6% of Medexus Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is EPI or MDP more profitable? Medexus Pharmaceuticals has a net margin of 3.25% compared to ESSA Pharma's net margin of 0.00%. Medexus Pharmaceuticals' return on equity of 11.07% beat ESSA Pharma's return on equity.Company Net Margins Return on Equity Return on Assets ESSA PharmaN/A N/A N/A Medexus Pharmaceuticals 3.25%11.07%4.89% Do analysts prefer EPI or MDP? Medexus Pharmaceuticals has a consensus target price of C$5.49, indicating a potential upside of 79.92%. Given Medexus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Medexus Pharmaceuticals is more favorable than ESSA Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ESSA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Medexus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 4 Strong Buy rating(s) 3.29 Which has stronger valuation & earnings, EPI or MDP? Medexus Pharmaceuticals has higher revenue and earnings than ESSA Pharma. ESSA Pharma is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioESSA PharmaN/AN/AN/A-C$0.99-8.27Medexus PharmaceuticalsC$105.66M0.93C$3.26MC$0.02152.50 Does the media prefer EPI or MDP? In the previous week, ESSA Pharma's average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score. Company Overall Sentiment ESSA Pharma Neutral Medexus Pharmaceuticals Neutral SummaryMedexus Pharmaceuticals beats ESSA Pharma on 12 of the 12 factors compared between the two stocks. Get Medexus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDP vs. The Competition Export to ExcelMetricMedexus PharmaceuticalsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$98.39MC$1.68BC$5.76BC$9.35BDividend YieldN/A2.93%6.67%6.53%P/E Ratio152.5066.0675.7124.90Price / Sales0.931,477.03548.179.32Price / CashN/A10.3737.0583.29Price / Book2.2512.1111.295.32Net IncomeC$3.26MC$20.70BC$3.29BC$301.20M7 Day PerformanceN/A-1.02%0.18%0.74%1 Month Performance5.54%2.11%6.30%6.43%1 Year Performance12.96%4.44%56.91%36.19% Medexus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDPMedexus PharmaceuticalsN/AC$3.05-0.7%C$5.49+79.9%+18.2%C$98.39MC$105.66M152.5098EPIESSA PharmaN/AC$8.20+7.2%N/A+0.0%C$237.87MN/A-8.2725Positive NewsICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533.68K95.29N/AGap UpRIVRIV CapitalN/AN/AN/AN/AC$213.65MC$11.33M-1.6312LEAFLeaf MobileN/AN/AN/AN/AC$198.42MC$83.74M58.86150Positive NewsRXBioSyentN/AC$12.05+0.4%N/A+10.9%C$137.82MC$34.06M19.56N/ANews CoverageCRDLCardiol TherapeuticsN/AC$1.58-1.3%N/A-41.2%C$131.11MN/A-3.1120HLSHLS Therapeutics0.3123 of 5 starsC$5.22-0.6%C$5.00-4.2%+72.3%C$116.13MC$40.13M-5.2391Positive NewsTGODGreen Organic DutchmanN/AN/AN/AN/AC$89.95MC$31.37M-0.6541Gap UpHigh Trading VolumeNINEDelta 9 CannabisN/AC$1.03+3.0%N/A+0.0%C$89.36MC$12.87M19.07940News CoverageGap UpSUGRSugarBud Craft GrowersN/AC$13.01-1.8%N/A+65.3%C$88.73MC$575.64M15.6744 Related Companies and Tools Related Companies ESSA Pharma Competitors ICC Labs Competitors RIV Capital Competitors Leaf Mobile Competitors BioSyent Competitors Cardiol Therapeutics Competitors HLS Therapeutics Competitors Green Organic Dutchman Competitors Delta 9 Cannabis Competitors SugarBud Craft Growers Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:MDP) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
